stock upgrade | GenomeWeb

stock upgrade

The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.

The investment bank said it has heard positive feedback from early adopters in Europe of GenMark's ePlex system and respiratory panel.

New products and a more normal 2016-17 flu season could accelerate revenues for Quidel, the investment bank said.

The investment bank said the company's stock has "swung to the upside" following a reimbursement decision from the Centers for Medicare and Medicaid Services.

The investment bank also raised its outlook on the life science tools sector, lowered its view of labs, and stayed steady on diagnostics.

The investment firm said the potential for T2's upcoming bacteria sepsis panel outweighs concerns over a lackluster launch for its Candida panel.

The cancer diagnostics firm could be poised for a return to growth following a transition that has seen its share price drop 16 percent in the year to date.

The investment bank noted stabilization in Myriad's BRCA1/2 testing franchise, the firm's new management, and its new products. 

The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.

Deals with Quest and LabCorp and an expanded product offering also spurred the investment bank to increase its price target on Cepheid's stock to $75 per share from $52.


In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.